Connection

Perry Halushka to Blood Platelets

This is a "connection" page, showing publications Perry Halushka has written about Blood Platelets.
Connection Strength

4.495
  1. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003 Jan; 73(1):122-30.
    View in: PubMed
    Score: 0.204
  2. Modification on ligand binding to TXA2/PGH2 receptors by diethylpyrocarbonate. Adv Exp Med Biol. 1997; 400A:235-40.
    View in: PubMed
    Score: 0.135
  3. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995 Jun 01; 91(11):2742-7.
    View in: PubMed
    Score: 0.121
  4. Inhibition of ligand binding to thromboxane A2/prostaglandin H2 receptors by diethylpyrocarbonate. Protection by receptor ligands and reversal by hydroxylamine. Biochem Pharmacol. 1995 Mar 30; 49(7):921-7.
    View in: PubMed
    Score: 0.119
  5. Testosterone regulation of platelet and vascular thromboxane A2 receptors. Agents Actions Suppl. 1995; 45:19-26.
    View in: PubMed
    Score: 0.117
  6. Androgen regulation of thromboxane A2 receptors. Adv Prostaglandin Thromboxane Leukot Res. 1995; 23:251-3.
    View in: PubMed
    Score: 0.117
  7. Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets. Am J Physiol. 1994 Sep; 267(3 Pt 2):H887-93.
    View in: PubMed
    Score: 0.115
  8. Agonist-induced phosphorylation of human platelet TXA2/PGH2 receptors. Biochim Biophys Acta. 1994 Mar 10; 1221(1):83-8.
    View in: PubMed
    Score: 0.111
  9. Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with pregnancy induced hypertension. Thromb Res. 1993 May 01; 70(3):205-10.
    View in: PubMed
    Score: 0.104
  10. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug; 262(2):632-7.
    View in: PubMed
    Score: 0.099
  11. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Jul; 262(1):238-45.
    View in: PubMed
    Score: 0.099
  12. Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human platelets. J Biol Chem. 1991 Jul 25; 266(21):13752-8.
    View in: PubMed
    Score: 0.092
  13. Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat. Biochem Pharmacol. 1991 Jul 15; 42(3):537-44.
    View in: PubMed
    Score: 0.092
  14. Interactions of dihydropyridine Ca2+ channel agonists with the human platelet thromboxane A2/prostaglandin H2 receptor. Eur J Pharmacol. 1991 Jan 25; 206(1):15-21.
    View in: PubMed
    Score: 0.089
  15. Characterization of thromboxane A2/prostaglandin H2 receptors of various tissues using a new radioiodinated thromboxane A2/prostaglandin H2 mimetic, I-BOP. Adv Prostaglandin Thromboxane Leukot Res. 1991; 21A:331-7.
    View in: PubMed
    Score: 0.089
  16. Photoaffinity receptor antagonist for human platelet thromboxane A2/prostaglandin H2 receptors. Biochem Pharmacol. 1990 Oct 01; 40(7):1457-61.
    View in: PubMed
    Score: 0.087
  17. Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with acute myocardial infarction. Circulation. 1990 Jan; 81(1):212-8.
    View in: PubMed
    Score: 0.083
  18. I-BOP, the most potent radiolabelled agonist for the TXA2/PGH2 receptor. Adv Prostaglandin Thromboxane Leukot Res. 1990; 20:102-9.
    View in: PubMed
    Score: 0.083
  19. Radioligand binding assays for thromboxane A2/prostaglandin H2 receptors. Methods Enzymol. 1990; 187:397-405.
    View in: PubMed
    Score: 0.083
  20. Human platelets modulate edema formation in isolated rabbit lungs. J Clin Invest. 1989 Sep; 84(3):757-64.
    View in: PubMed
    Score: 0.081
  21. Photoaffinity labelling of the human platelet thromboxane A2/prostaglandin H2 receptor. Biochim Biophys Acta. 1989 Jul 11; 1012(2):184-90.
    View in: PubMed
    Score: 0.080
  22. Photoaffinity labelling and isoelectric focusing of the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor. Adv Prostaglandin Thromboxane Leukot Res. 1989; 19:168-71.
    View in: PubMed
    Score: 0.077
  23. Photoaffinity labelling of the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor. Prog Clin Biol Res. 1989; 301:303-7.
    View in: PubMed
    Score: 0.077
  24. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun. 1988 Dec 15; 157(2):733-9.
    View in: PubMed
    Score: 0.077
  25. Desensitization of platelet thromboxane A2/prostaglandin H2 receptors by the mimetic U46619. J Pharmacol Exp Ther. 1988 Dec; 247(3):1133-8.
    View in: PubMed
    Score: 0.077
  26. Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels. Eur J Pharmacol. 1988 Apr 13; 148(3):309-15.
    View in: PubMed
    Score: 0.074
  27. Subcellular localization of a thromboxane A2/prostaglandin H2 receptor antagonist binding site in human platelets. Biochem Pharmacol. 1988 Feb 15; 37(4):647-54.
    View in: PubMed
    Score: 0.073
  28. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant. Biochem Pharmacol. 1987 Jun 15; 36(12):1913-7.
    View in: PubMed
    Score: 0.069
  29. Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets. Prostaglandins. 1987 Jun; 33(6):789-97.
    View in: PubMed
    Score: 0.069
  30. Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol. 1987 May; 91(1):223-7.
    View in: PubMed
    Score: 0.069
  31. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors. Fed Proc. 1987 Jan; 46(1):149-53.
    View in: PubMed
    Score: 0.067
  32. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to guinea-pig platelets. Eur J Pharmacol. 1986 Nov 12; 131(1):49-54.
    View in: PubMed
    Score: 0.067
  33. Photoaffinity labelling of a thromboxane A2/prostaglandin H2 antagonist binding site in human platelets. Biochem Biophys Res Commun. 1986 Oct 15; 140(1):128-33.
    View in: PubMed
    Score: 0.066
  34. Identification of a putative thromboxane A2/prostaglandin H2 receptor in human platelet membranes. J Biol Chem. 1986 Mar 05; 261(7):3025-9.
    View in: PubMed
    Score: 0.064
  35. Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation. 1985 Dec; 72(6):1202-7.
    View in: PubMed
    Score: 0.062
  36. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. J Pharmacol Exp Ther. 1985 Dec; 235(3):729-34.
    View in: PubMed
    Score: 0.062
  37. Hydrodynamic properties of a thromboxane A2/prostaglandin H2 antagonist binding site solubilized from human platelets. Biochem Biophys Res Commun. 1985 Nov 15; 132(3):961-8.
    View in: PubMed
    Score: 0.062
  38. Solubilization of a thromboxane A2/prostaglandin H2 antagonist binding site from human platelets. Proc Natl Acad Sci U S A. 1985 Nov; 82(21):7434-8.
    View in: PubMed
    Score: 0.062
  39. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets. Mol Pharmacol. 1985 Aug; 28(2):163-9.
    View in: PubMed
    Score: 0.061
  40. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther. 1985 May; 233(2):418-24.
    View in: PubMed
    Score: 0.060
  41. Further studies on the effects of epimers of thromboxane A2 antagonists on platelets and veins. Eur J Pharmacol. 1985 Apr 23; 111(1):125-8.
    View in: PubMed
    Score: 0.060
  42. Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM. 2005 May; 98(5):349-56.
    View in: PubMed
    Score: 0.060
  43. Do platelets have anything to do with diabetic microvascular disease? Diabetes. 1983 May; 32 Suppl 2:14-9.
    View in: PubMed
    Score: 0.052
  44. Platelets, prostaglandins, and coagulation in diabetes mellitus. Mt Sinai J Med. 1982 May-Jun; 49(3):215-22.
    View in: PubMed
    Score: 0.049
  45. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002 Apr 09; 105(14):1620-2.
    View in: PubMed
    Score: 0.048
  46. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res. 1981 Nov 15; 24(4):307-17.
    View in: PubMed
    Score: 0.047
  47. Increased platelet arachidonic acid metabolism in diabetes mellitus. Diabetes. 1981; 30(Suppl 2):44-8.
    View in: PubMed
    Score: 0.044
  48. Increased platelet prostaglandin and thromboxane synthesis in diabetes mellitus. Horm Metab Res Suppl. 1981; 11:7-11.
    View in: PubMed
    Score: 0.044
  49. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med. 1981 Jan; 97(1):87-96.
    View in: PubMed
    Score: 0.044
  50. Platelet function in diabetes mellitus. Br J Haematol. 1980 Apr; 44(4):521-6.
    View in: PubMed
    Score: 0.042
  51. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 Aug; 76(8):4097-101.
    View in: PubMed
    Score: 0.040
  52. Prostaglandins, thromboxanes, and platelet function. Curr Top Hematol. 1979; 2:75-143.
    View in: PubMed
    Score: 0.039
  53. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1998 Apr 28; 95(9):4888-93.
    View in: PubMed
    Score: 0.037
  54. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N Engl J Med. 1977 Dec 15; 297(24):1306-10.
    View in: PubMed
    Score: 0.036
  55. Inhibition of testosterone 5 alpha-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. J Pharmacol Exp Ther. 1996 Dec; 279(3):1386-91.
    View in: PubMed
    Score: 0.033
  56. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. J Pharmacol Exp Ther. 1994 Sep; 270(3):1192-6.
    View in: PubMed
    Score: 0.029
  57. Thromboxane A2/prostaglandin H2 receptors in streptozotocin-induced diabetes: effects of insulin therapy in the rat. Prostaglandins. 1993 May; 45(5):427-38.
    View in: PubMed
    Score: 0.026
  58. Characterization of rat glomerular thromboxane A2 receptors: comparison to rat platelets. Eur J Pharmacol. 1992 Sep 01; 227(1):71-8.
    View in: PubMed
    Score: 0.025
  59. Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. J Med Chem. 1991 Apr; 34(4):1511-4.
    View in: PubMed
    Score: 0.023
  60. Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul; 86(14):5600-4.
    View in: PubMed
    Score: 0.020
  61. Thromboxane and prostacyclin receptors. Prog Clin Biol Res. 1989; 301:21-8.
    View in: PubMed
    Score: 0.019
  62. Human platelets attenuate oxidant injury in isolated rabbit lungs. J Appl Physiol (1985). 1988 Sep; 65(3):1258-66.
    View in: PubMed
    Score: 0.019
  63. Polymyxin B increases TXA2/PGH2 agonist and antagonist affinities in human platelet membranes. Eicosanoids. 1988; 1(1):41-4.
    View in: PubMed
    Score: 0.018
  64. Macrophage eicosanoid formation is stimulated by platelet arachidonic acid and prostaglandin endoperoxide transfer. Biochim Biophys Acta. 1987 Mar 19; 923(3):355-61.
    View in: PubMed
    Score: 0.017
  65. Insulin and arachidonic acid metabolism in diabetes mellitus. Metabolism. 1985 Dec; 34(12 Suppl 1):32-6.
    View in: PubMed
    Score: 0.016
  66. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
    View in: PubMed
    Score: 0.016
  67. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983 Nov 30; 75(5B):67-80.
    View in: PubMed
    Score: 0.014
  68. Hydrogen bond interactions of a series of N-substituted TXA2 receptor antagonists. Eur J Med Chem. 2003 Nov-Dec; 38(11-12):1015-24.
    View in: PubMed
    Score: 0.014
  69. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells. J Pharmacol Exp Ther. 2003 Dec; 307(3):1142-7.
    View in: PubMed
    Score: 0.013
  70. Studies on the beneficial effects of aspirin in endotoxic shock. Relationship to inhibition of arachidonic acid metabolism. Am J Med. 1983 Jun 14; 74(6A):91-6.
    View in: PubMed
    Score: 0.013
  71. Arachidonic acid metabolism in endotoxin tolerance. Adv Shock Res. 1983; 10:131-42.
    View in: PubMed
    Score: 0.013
  72. Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care. 1981 Jan-Feb; 4(1):121-33.
    View in: PubMed
    Score: 0.011
  73. Altered platelet function in diabetes mellitus. Diabetes. 1976; 25(2 SUPPL):826-31.
    View in: PubMed
    Score: 0.008
  74. Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia. Neurology. 1986 Apr; 36(4):466-70.
    View in: PubMed
    Score: 0.004
  75. A novel approach for the study of thromboxane A2 and prostaglandin H2 receptors using an 125I-labeled ligand. Biochem Pharmacol. 1985 Apr 15; 34(8):1165-70.
    View in: PubMed
    Score: 0.004
  76. Platelet adhesion and aggregation in diabetes mellitus. Metabolism. 1979 Apr; 28(4 Suppl 1):394-400.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.